These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 26108998)

  • 21. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
    Ramakrishnan V; Kimlinger T; Haug J; Painuly U; Wellik L; Halling T; Rajkumar SV; Kumar S
    PLoS One; 2012; 7(11):e50005. PubMed ID: 23185517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
    Ripple MO; Kalmadi S; Eastman A
    Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).
    Holt SV; Logie A; Davies BR; Alferez D; Runswick S; Fenton S; Chresta CM; Gu Y; Zhang J; Wu YL; Wilkinson RW; Guichard SM; Smith PD
    Cancer Res; 2012 Apr; 72(7):1804-13. PubMed ID: 22271687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways.
    Penuel E; Martin GS
    Mol Biol Cell; 1999 Jun; 10(6):1693-703. PubMed ID: 10359590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].
    Li ZW; Yang ZL; Feng HL; Bian XC; Liu YY; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):330-5. PubMed ID: 24004591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways.
    Qiu Q; Yang M; Tsang BK; Gruslin A
    Reproduction; 2004 Sep; 128(3):355-63. PubMed ID: 15333786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crosstalk between Raf/MEK/ERK and PI3K/AKT in suppression of Bax conformational change by Grp75 under glucose deprivation conditions.
    Yang L; Guo W; Zhang Q; Li H; Liu X; Yang Y; Zuo J; Liu W
    J Mol Biol; 2011 Dec; 414(5):654-66. PubMed ID: 21964438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
    Hartmann W; Küchler J; Koch A; Friedrichs N; Waha A; Endl E; Czerwitzki J; Metzger D; Steiner S; Wurst P; Leuschner I; von Schweinitz D; Buettner R; Pietsch T
    Clin Cancer Res; 2009 Jul; 15(14):4538-45. PubMed ID: 19584164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
    Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway.
    Yu C; Mao X; Li WX
    Biochem Biophys Res Commun; 2005 Jun; 331(2):391-7. PubMed ID: 15850772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
    Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
    Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
    Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
    Mahoney CL; Choudhury B; Davies H; Edkins S; Greenman C; Haaften Gv; Mironenko T; Santarius T; Stevens C; Stratton MR; Futreal PA
    Br J Cancer; 2009 Jan; 100(2):370-5. PubMed ID: 19165201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
    Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
    Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of the PI3K-AKT-mTOR signaling pathway promotes DEHP-induced Hep3B cell proliferation.
    Chen X; Qin Q; Zhang W; Zhang Y; Zheng H; Liu C; Yang Y; Xiong W; Yuan J
    Food Chem Toxicol; 2013 Sep; 59():325-33. PubMed ID: 23793038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
    Simmons BH; Lee JH; Lalwani K; Giddabasappa A; Snider BA; Wong A; Lappin PB; Eswaraka J; Kan JL; Christensen JG; Shojaei F
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):213-20. PubMed ID: 22684718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
    Kinross KM; Brown DV; Kleinschmidt M; Jackson S; Christensen J; Cullinane C; Hicks RJ; Johnstone RW; McArthur GA
    Mol Cancer Ther; 2011 Aug; 10(8):1440-9. PubMed ID: 21632463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
    Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA
    Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
    Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J
    Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.